Diagnostic and Prognostic Value of Liquid Biopsies in Non-Invasive Cancer Monitoring
DOI:
https://doi.org/10.56294/mw2024536Keywords:
Liquid biopsy, Cancer detection, Circulating tumor DNA (ctDNA), Minimal residual disease (MRD), Prognostic monitoringAbstract
Researchers are finding that liquid biopsies, which are samples of blood, saliva, or pee that are not solid, can be used to find biomarkers that can help diagnose and track cancer. Traditional tissue biopsies are invasive and may not always be possible. Liquid biopsies, on the other hand, can be used over and over again and in real time to find genetic changes linked to cancer, differences in tumors, and treatment reactions. This piece talks about the diagnostic and predictive worth of liquid samples in cancer care. It focuses on how they can help with early diagnosis, tracking the development of the disease, figuring out the minimal residual disease (MRD), and guessing how well treatment will work. A liquid biopsy has gotten a lot of attention as an early cancer screening method because it can find genetic changes early on, often before any signs show up. It is possible to find cancer-related changes in cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs) using liquid samples. This information can help with early action and specific treatment plans. Liquid biopsies also show differences between tumors and how genes change over time, which is very important for figuring out how drug resistance works. Liquid biopsy has been very helpful for figuring out how well treatment is working and finding relapses. Monitoring ctDNA levels in real time can show how much of a tumor there is, which lets doctors see how well treatment is working and make changes to treatment plans as required. The amount and prevalence of ctDNA have been linked to tumor growth, showing an early sign of recurrence even before regular imaging methods show disease that can be seen by a doctor.
References
Zhu, S.; Fang, Y.; Guo, K.; Zhang, N.; Xiang, N. Next-generation Liquid Biopsy Instruments: Challenges and Opportunities. Electrophoresis 2023, 44, 775–783.
Gao, W.; Chen, Y.; Yang, J.; Zhuo, C.; Zhang, H.; Shi, Y. Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer. Front. Genet. 2021, 12, 634642.
Rastogi, A. Changing Role of Histopathology in the Diagnosis and Management of Hepatocellular Carcinoma. World J. Gastroenterol. 2018, 24, 4000–4013.
Hirahata, T.; Ul Quraish, R.; Quraish, A.U.; Ul Quraish, S.; Naz, M.; Razzaq, M.A. Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer. Cancer Inform. 2022, 21, 11769351221076062.
Adhit, K.K.; Wanjari, A.; Menon, S.; Siddhaarth, K. Liquid Biopsy: An Evolving Paradigm for Non-invasive Disease Diagnosis and Monitoring in Medicine. Cureus 2023, 15, e50176.
Russano, M.; Napolitano, A.; Ribelli, G.; Iuliani, M.; Simonetti, S.; Citarella, F.; Pantano, F.; Dell’Aquila, E.; Anesi, C.; Silvestris, N.; et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: The potentiality of blood samples. J. Exp. Clin. Cancer Res. 2020, 39, 95.
Jin, N.; Kan, C.-M.; Pei, X.M.; Cheung, W.L.; Ng, S.S.M.; Wong, H.T.; Cheng, H.Y.-L.; Leung, W.W.; Wong, Y.N.; Tsang, H.F.; et al. Cell-free circulating tumor RNAs in plasma as the potential prognostic biomarkers in colorectal cancer. Front. Oncol. 2023, 13, 1134445.
Ilie, M.; Hofman, P. Pros: Can tissue biopsy be replaced by liquid biopsy? Transl. Lung Cancer Res. 2016, 5, 420–423.
Vidlarova, M.; Rehulkova, A.; Stejskal, P.; Prokopova, A.; Slavik, H.; Hajduch, M.; Srovnal, J. Recent Advances in Methods for Circulating Tumor Cell Detection. Int. J. Mol. Sci. 2023, 24, 3902.
Liu, Y.; Wang, Y.; Sun, S.; Chen, Z.; Xiang, S.; Ding, Z.; Huang, Z.; Zhang, B. Understanding the versatile roles and applications of EpCAM in cancers: From bench to bedside. Exp. Hematol. Oncol. 2022, 11, 97.
Lin, D.; Shen, L.; Luo, M.; Zhang, K.; Li, J.; Yang, Q.; Zhu, F.; Zhou, D.; Zheng, S.; Chen, Y.; et al. Circulating tumor cells: Biology and clinical significance. Signal Transduct. Target. Ther. 2021, 6, 404.
Wu, T.M.; Liu, J.B.; Liu, Y.; Shi, Y.; Li, W.; Wang, G.R.; Ma, Y.S.; Fu, D. Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control. Cancer Control 2020, 27, 1073274820934805.
Descamps, L.; Le Roy, D.; Deman, A.-L. Microfluidic-Based Technologies for CTC Isolation: A Review of 10 Years of Intense Efforts towards Liquid Biopsy. Int. J. Mol. Sci. 2022, 23, 1981
Yadav, A.; Kumar, A.; Siddiqui, M.H. Detection of circulating tumour cells in colorectal cancer: Emerging techniques and clinical implications. World J. Clin. Oncol. 2021, 12, 1169–1181.
Wiegmans, A.P.; Ivanova, E.; Naei, V.Y.; Monkman, J.; Fletcher, J.; Mullally, W.; Warkiani, M.E.; O’Byrne, K.; Kulasinghe, A. Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer. Clin. Exp. Metastasis 2024, 41, 219–228.
Armakolas, A.; Kotsari, M.; Koskinas, J. Liquid Biopsies, Novel Approaches and Future Directions. Cancers 2023, 15, 1579. [Google Scholar] [CrossRef] [PubMed]
Habli, Z.; AlChamaa, W.; Saab, R.; Kadara, H.; Khraiche, M.L. Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities. Cancers 2020, 12, 1930.
Lemma, S.; Perrone, A.M.; De Iaco, P.; Gasparre, G.; Kurelac, I. Current methodologies to detect circulating tumor cells: A focus on ovarian cancer. Am. J. Cancer Res. 2021, 11, 4111–4126.
Chu, P.Y.; Hsieh, C.H.; Wu, M.H. The Combination of Immunomagnetic Bead-Based Cell Isolation and Optically Induced Dielectrophoresis (ODEP)-Based Microfluidic Device for the Negative Selection-Based Isolation of Circulating Tumor Cells (CTCs). Front. Bioeng. Biotechnol. 2020, 8, 921.
Eslami-S, Z.; Cortés-Hernández, L.E.; Alix-Panabières, C. Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells. Cells 2020, 9, 1836.
Fridrichova, I.; Kalinkova, L.; Ciernikova, S. Clinical Relevancy of Circulating Tumor Cells in Breast Cancer: Epithelial or Mesenchymal Characteristics, Single Cells or Clusters? Int. J. Mol. Sci. 2022, 23, 12141.
Guan, Y.; Xu, F.; Tian, J.; Chen, H.; Yang, C.; Huang, S.; Gao, K.; Wan, Z.; Li, M.; He, M.; et al. Pathology of circulating tumor cells and the available capture tools (Review). Oncol. Rep. 2020, 43, 1355–1364.
Hassan, S.; Blick, T.; Williams, E.D.; Thompson, E.W. Applications of RNA characterisation in circulating tumour cells. Front. Biosci.-Landmark 2020, 25, 874–892.
Kalinich, M.; Kwan, T.T.; Toner, M.; Haber, D.A.; Maheswaran, S. Quantitative Analysis of Circulating Tumor Cells Using RNA-Based Digital Scoring. In Tumor Liquid Biopsies; Schaffner, F., Merlin, J.-L., von Bubnoff, N., Eds.; Springer: Cham, Switzerland, 2020; pp. 77–88.
Published
Issue
Section
License
Copyright (c) 2024 Sujayaraj Samuel Jayakumar, Lokesh Ravilla, Jagmeet Sohal, Swarna Swetha Kolaventi, Divya Sharma, Niranjan Sahu, Money Saxena (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
